Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|November 1, 2002
The American Journal of Managed Care
- November 2002
- Volume 8
- Issue 11
Pill Splitting
Advertisement
Articles in this issue
almost 24 years ago
Antibiotic Resistance: The Iowa Experiencealmost 24 years ago
Therapeutic Options for the Management of Type 2 Diabetes MellitusAdvertisement
Related to this article
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5